Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

970
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
970
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

671
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
671
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

935
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
935
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K
Stimulants01:29

Stimulants

1.0K
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
1.0K
Drug Therapy01:28

Drug Therapy

315
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Definition of treatment-resistant late-life depression: Conclusions from a European Task Force Delphi process.

European psychiatry : the journal of the Association of European Psychiatrists·2026
Same author

Association between benzodiazepine receptor agonist use and mortality in patients hospitalised for COVID-19: a multicentre observational study.

Epidemiology and psychiatric sciences·2022
Same author

[Smoking behaviours among staff of two university hospitals in Paris, 2021].

Revue des maladies respiratoires·2022
Same author

[Smoking cessation services during "Mois sans tabac": Smokers' profile and effectiveness].

Revue des maladies respiratoires·2021
Same author

Temporal trajectory of brain tissue property changes induced by electroconvulsive therapy.

NeuroImage·2021
Same author

Does substance use explain social differences in terms of depression? Findings from the Constances cohort.

Comprehensive psychiatry·2020

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K

[Psychostimulants for late life depression].

P Delsalle1, J-P Schuster2, A von Gunten3

  • 1Service de psychiatrie de l'adulte et du sujet âgé, centre ressource régional de psychiatrie du sujet âgé d'Île-de-France, Assistance publique-Hôpitaux de Paris (AP-HP), HUPO, hôpital Corentin-Celton, 4, parvis Corentin-Celton, 92130 Issy-les-Moulineaux, France.

L'Encephale
|December 3, 2017
PubMed
Summary

Psychostimulants like methylphenidate show potential as add-on therapy for elderly depression. However, insufficient evidence from small, limited studies necessitates further research for definitive conclusions.

Keywords:
DepressionDépressionOld age psychiatryPsychiatrie du sujet âgéPsychostimulantPsychostimulants

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

886
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

22.4K

Related Experiment Videos

Last Updated: Feb 17, 2026

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System
05:59

Author Spotlight: Overcoming Challenges in Drosophila Sleep Measurement Using DAM System

Published on: October 20, 2023

3.2K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

886
A New Method for Inducing a Depression-Like Behavior in Rats
07:57

A New Method for Inducing a Depression-Like Behavior in Rats

Published on: February 22, 2018

22.4K

Area of Science:

  • Geriatric Psychiatry
  • Pharmacological Treatments
  • Mental Health Research

Background:

  • Psychostimulant use for depressive disorders is gaining attention.
  • There is a specific interest in their application for geriatric depression.

Purpose of the Study:

  • To review existing literature on psychostimulants for treating depression in older adults.
  • To assess the efficacy and tolerability of these treatments.

Main Methods:

  • Literature review of studies published between 1980 and 2016.
  • Inclusion criterion: average participant age of 60 years or older.
  • Analysis of 12 trials (3 controlled, 9 uncontrolled).

Main Results:

  • Methylphenidate was the most frequently studied psychostimulant.
  • Evidence suggests potential efficacy as an add-on therapy for late-life depression.
  • The level of proof for efficacy remains largely insufficient.

Conclusions:

  • Small sample sizes and methodological limitations hinder definitive conclusions.
  • Further rigorous studies are needed, especially for treatment-resistant depression in the elderly.